Does financial hardship associate with abnormal quantitative myocardial perfusion and major adverse cardiovascular event?

CAD Diagnostic and prognostic application Diseases/processes Modalities Myocardial blood flow Outcomes PET Tests

Journal

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 01 03 2022
accepted: 25 11 2022
medline: 21 1 2024
pubmed: 21 1 2024
entrez: 20 1 2024
Statut: ppublish

Résumé

Data on impact of financial hardship on coronary artery disease (CAD) remain incomplete. Consecutive subjects referred for clinical rest/stress cardiac positron emission tomography (PET) were enrolled. Financial hardship is defined as patients' inability to pay for their out-of-pocket expense for cardiac PET. Abnormal cardiac PET is defined as at least moderate relative perfusion defects at stress involving > 10% of the left ventricle or global coronary flow reserve ≤ 2.0. Patients were followed for major adverse cardiovascular event (MACE) comprised of all-cause mortality, non-fatal myocardial infarction, and late coronary revascularization. We analyzed a total of 4173 patients with mean age 65.6 ± 11.3 years, 72.2% men, and 93.6% reported as having medical insurance. Of these, 504 (12.1%) patients had financial hardship. On multivariable analysis, financial hardship associated with abnormal cardiac PET (odds ratio 1.377, p = 0.004) and MACE (hazard ratio 1.432, p = 0.010) and its association with MACE was mostly through direct effect with small proportion mediated by abnormal cardiac PET or known CAD. Among patients referred for cardiac rest/stress PET, financial hardship independently associates with myocardial perfusion abnormalities and MACE; however, its effect on MACE is largely not mediated by abnormal myocardial perfusion or known CAD suggesting distinct impact of financial hardship beyond traditional risk factors and CAD that deserves attention and intervention to effectively reduced adverse outcomes. Having medical insurance does not consistently protect from financial hardship and a more preventive-oriented restructuring may provide better outcomes at lower cost.

Sections du résumé

BACKGROUND BACKGROUND
Data on impact of financial hardship on coronary artery disease (CAD) remain incomplete.
METHODS METHODS
Consecutive subjects referred for clinical rest/stress cardiac positron emission tomography (PET) were enrolled. Financial hardship is defined as patients' inability to pay for their out-of-pocket expense for cardiac PET. Abnormal cardiac PET is defined as at least moderate relative perfusion defects at stress involving > 10% of the left ventricle or global coronary flow reserve ≤ 2.0. Patients were followed for major adverse cardiovascular event (MACE) comprised of all-cause mortality, non-fatal myocardial infarction, and late coronary revascularization.
RESULTS RESULTS
We analyzed a total of 4173 patients with mean age 65.6 ± 11.3 years, 72.2% men, and 93.6% reported as having medical insurance. Of these, 504 (12.1%) patients had financial hardship. On multivariable analysis, financial hardship associated with abnormal cardiac PET (odds ratio 1.377, p = 0.004) and MACE (hazard ratio 1.432, p = 0.010) and its association with MACE was mostly through direct effect with small proportion mediated by abnormal cardiac PET or known CAD.
CONCLUSION CONCLUSIONS
Among patients referred for cardiac rest/stress PET, financial hardship independently associates with myocardial perfusion abnormalities and MACE; however, its effect on MACE is largely not mediated by abnormal myocardial perfusion or known CAD suggesting distinct impact of financial hardship beyond traditional risk factors and CAD that deserves attention and intervention to effectively reduced adverse outcomes. Having medical insurance does not consistently protect from financial hardship and a more preventive-oriented restructuring may provide better outcomes at lower cost.

Identifiants

pubmed: 38245281
pii: S1071-3581(24)00051-5
doi: 10.1007/s12350-022-03184-1
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1528-1539

Informations de copyright

Copyright © 2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved.

Auteurs

Danai Kitkungvan (D)

Division of Cardiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

Nils P Johnson (NP)

Division of Cardiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

Linh Bui (L)

Division of Cardiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

Monica B Patel (MB)

Division of Cardiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

Amanda E Roby (AE)

Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

Mary Haynie (M)

Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

Richard Kirkeeide (R)

Division of Cardiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

Susan Hood (S)

Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

K Lance Gould (KL)

Division of Cardiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; Weatherhead PET Center For Preventing and Reversing Atherosclerosis, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: K.Lance.Gould@uth.tmc.edu.

Classifications MeSH